Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Daratumumab + Chemotherapy Safety & Efficacy In Newly Diagnosed T-ALL & T-LL
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 18, 2025
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 05, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
SPARK-ALL: Calaspargase Pegol in Adults with ALL
Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 26, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable